No Data
Express News | Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17TH Annual Clinical Trials on Alzheimer’s Disease (Ctad) Conference
Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference
Lucy Therapeutics Appoints Kim Drapkin as Board Chair
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV) and Acumen Pharmaceuticals (ABOS)
Stifel Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $10
Strong Buy Rating for Acumen Pharmaceuticals Amid Promising Trial Results for Lead Candidate ACU193